Rosanna Cannatelli1,2, Alina Bazarova3, Davide Zardo4, Olga Maria Nardone1, Uday Shivaji1,5, Samuel Charles Lloyd Smith1,5, Georgios Gkoutos1, Chiara Ricci2,6, Xianyong Sean Gui7, Subrata Ghosh1,5,8, Marietta Iacucci1,5,8. 1. Institute of Translational Medicine, University of Birmingham, UK. 2. Gastroenterology Unit, Spedali Civili di Brescia, Italy. 3. Institute for Biological Physics, University of Cologne, Germany. 4. Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom. 5. NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK. 6. Department of Clinical and Sperimental Sciences, University of Brescia, Italy. 7. Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA. 8. IBD Unit, University of Calgary, Calgary, AB, Canada.
Abstract
BACKGROUND: Fecal calprotectin (FC) is a common surrogate marker of mucosal healing (MH) in patients with ulcerative colitis (UC) and Crohn's disease (CD). We investigated the optimum FC thresholds for defining endoscopic remission (ER) and histological remission (HR) using advanced endoscopic techniques. PATIENTS AND METHODS: In this cross-sectional study, we collected clinical, endoscopic, histological data, and FC from 76 UC and 41 CD patients. Receiver operating characteristic curves were created to evaluate the optimum cut-off of FC to predict ER evaluated by Mayo Endoscopic Score (MES), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and modified PICaSSO (Paddington International Virtual Chromoendoscopy Score) for UC patients and Simple Endoscopic Score (SES-CD) in CD patients; and HR was scored by the Robarts Histology Index (RHI) and Nancy Index for UC and modified Riley for CD. RESULTS: In UC patients, the best thresholds of FC to identify ER calculated with MES, UCEIS, and modified PICaSSO were 112, 148, and 161 mcg/g with accuracy of 86.9% 86.8%, and 81.6%, respectively. The best value of FC to predict HR was 112 mcg/g and 172 mcg/g with accuracy of 84.2% and 81.6% for RHI and Nancy Index, respectively.In CD patients, the best cut-off of FC to predict ER was 96 mcg/g with accuracy of 82.9%. The HR was best predicted by an FC value of 225 mcg/g with accuracy of 75.6%. CONCLUSIONS: The FC value threshold between 112 and 172 mcg/g could identify ER and HR in UC patients, whereas a value under 225 mcg/g should be considered for CD patients.
BACKGROUND: Fecal calprotectin (FC) is a common surrogate marker of mucosal healing (MH) in patients with ulcerative colitis (UC) and Crohn's disease (CD). We investigated the optimum FC thresholds for defining endoscopic remission (ER) and histological remission (HR) using advanced endoscopic techniques. PATIENTS AND METHODS: In this cross-sectional study, we collected clinical, endoscopic, histological data, and FC from 76 UC and 41 CD patients. Receiver operating characteristic curves were created to evaluate the optimum cut-off of FC to predict ER evaluated by Mayo Endoscopic Score (MES), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and modified PICaSSO (Paddington International Virtual Chromoendoscopy Score) for UC patients and Simple Endoscopic Score (SES-CD) in CD patients; and HR was scored by the Robarts Histology Index (RHI) and Nancy Index for UC and modified Riley for CD. RESULTS: In UC patients, the best thresholds of FC to identify ER calculated with MES, UCEIS, and modified PICaSSO were 112, 148, and 161 mcg/g with accuracy of 86.9% 86.8%, and 81.6%, respectively. The best value of FC to predict HR was 112 mcg/g and 172 mcg/g with accuracy of 84.2% and 81.6% for RHI and Nancy Index, respectively.In CD patients, the best cut-off of FC to predict ER was 96 mcg/g with accuracy of 82.9%. The HR was best predicted by an FC value of 225 mcg/g with accuracy of 75.6%. CONCLUSIONS: The FC value threshold between 112 and 172 mcg/g could identify ER and HR in UC patients, whereas a value under 225 mcg/g should be considered for CD patients.
Authors: Fangwen Zou; Xuemei Wang; Isabella C Glitza Oliva; Jennifer L McQuade; Jennifer Wang; Hao Chi Zhang; John A Thompson; Anusha S Thomas; Yinghong Wang Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751
Authors: Monica State; Lucian Negreanu; Theodor Voiosu; Andrei Voiosu; Paul Balanescu; Radu Bogdan Mateescu Journal: World J Gastroenterol Date: 2021-04-28 Impact factor: 5.742
Authors: Brenda Maldonado-Arriaga; Sergio Sandoval-Jiménez; Juan Rodríguez-Silverio; Sofía Lizeth Alcaráz-Estrada; Tomás Cortés-Espinosa; Rebeca Pérez-Cabeza de Vaca; Jonathan Shaw; Paul Mondragón-Terán; Cecilia Hernández-Cortez; Juan Antonio Suárez-Cuenca; Graciela Castro-Escarpulli Journal: F1000Res Date: 2020-12-21